Highlights Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:54 2024-04-30 am EDT			5-day change	1st Jan Change
5,272 ^ILa	+6.87%		+7.92%	+38.19%

04:50pm	FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	MT
02:03pm	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	10:50am	MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	08:03am	MT
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	Apr. 22	MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17	CI
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	Apr. 16	DJ
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	Apr. 11	MT
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	Apr. 11	CI
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	Apr. 04	MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	Apr. 03	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics	Apr. 01	MT
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week	Feb. 26	MT
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO	Feb. 20	RE
High-dose opioid reversal spray no better than lower dose in field, US study finds	Feb. 08	RE
Teva Pharmaceutical's Q4 Non-GAAP Earnings, Revenue Rise; Provides 2024 Guidance	Jan. 31	MT
Teva Pharm profit handily beats Q4 estimates, sales jump	Jan. 31	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT